NASDAQ:CYCN - Cyclerion Therapeutics Stock Price, Forecast & News

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Cyclerion Therapeutics Inc (NASDAQ:CYCN) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.00) earnings per share for the quarter. The company had revenue of $1.40 million for the quarter. View Cyclerion Therapeutics' Earnings History.

Cyclerion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Cyclerion Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cyclerion Therapeutics.

Media stories about CYCN stock have trended positive on Saturday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cyclerion Therapeutics earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Cyclerion Therapeutics.

Cyclerion Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,260,000 shares, an increase of 5.9% from the October 31st total of 1,190,000 shares. Based on an average daily volume of 349,900 shares, the short-interest ratio is presently 3.6 days. Currently, 4.8% of the shares of the stock are sold short. View Cyclerion Therapeutics' Current Options Chain.

Some companies that are related to Cyclerion Therapeutics include Mirum Pharmaceuticals (MIRM), Spero Therapeutics (SPRO), XOMA (XOMA), Satsuma Pharmaceuticals (STSA), Athersys (ATHX), Ovid Therapeutics (OVID), Syros Pharmaceuticals (SYRS), Cerecor (CERC), Protagonist Therapeutics (PTGX), Ocular Therapeutix (OCUL), Nature's Sunshine Products (NATR), AcelRx Pharmaceuticals (ACRX), Mersana Therapeutics (MRSN), Concert Pharmaceuticals (CNCE) and Abeona Therapeutics (ABEO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Lexicon Pharmaceuticals (LXRX), ACADIA Pharmaceuticals (ACAD), Agenus (AGEN), Arrowhead Pharmaceuticals (ARWR), Antares Pharma (ATRS), BioCryst Pharmaceuticals (BCRX), Cara Therapeutics (CARA), Catabasis Pharmaceuticals (CATB), Cidara Therapeutics (CDTX) and Celldex Therapeutics (CLDX).

Cyclerion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (1.65%), Russell Investments Group Ltd. (0.33%), Squarepoint Ops LLC (0.32%), California State Teachers Retirement System (0.13%), First Trust Advisors LP (0.13%) and California Public Employees Retirement System (0.12%). Company insiders that own Cyclerion Therapeutics stock include Amy W Schulman, Andreas Busch, Mark G Currie and William Huyett. View Institutional Ownership Trends for Cyclerion Therapeutics.

CYCN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Russell Investments Group Ltd., Squarepoint Ops LLC, California State Teachers Retirement System, First Trust Advisors LP, California Public Employees Retirement System, Broderick Brian C and Barclays PLC. Company insiders that have bought Cyclerion Therapeutics stock in the last two years include Amy W Schulman, Andreas Busch and Mark G Currie. View Insider Buying and Selling for Cyclerion Therapeutics.

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYCN stock can currently be purchased for approximately $1.96.

Cyclerion Therapeutics has a market capitalization of $53.84 million. View Additional Information About Cyclerion Therapeutics.

The official website for Cyclerion Therapeutics is http://www.cyclerion.com/.

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]